Grifols S.A. (GRFS)
7.29
-0.02 (-0.27%)
At close: Mar 28, 2025, 3:59 PM
7.27
-0.21%
After-hours: Mar 28, 2025, 04:00 PM EDT
-0.27% (1D)
| Bid | 7.1 |
| Market Cap | 5.84B |
| Revenue (ttm) | 8.43B |
| Net Income (ttm) | 183.4M |
| EPS (ttm) | 0.25 |
| PE Ratio (ttm) | 29.14 |
| Forward PE | 6.88 |
| Analyst | n/a |
| Ask | 7.4 |
| Volume | 562,486 |
| Avg. Volume (20D) | 1,008,900 |
| Open | 7.28 |
| Previous Close | 7.31 |
| Day's Range | 7.20 - 7.32 |
| 52-Week Range | 5.79 - 9.96 |
| Beta | 0.69 |
About GRFS
Grifols, S.A. engages in the procurement, manufacture, preparation, and sale of therapeutic products, primarily hemoderivatives. The company operates through Bioscience, Hospital, Diagnostic, Bio Supplies, and Others divisions. The Bioscience division researches, develops, produces, and markets plasma-derived medicines and other innovative solutions to treat patients with chronic, rare, prevalent, and life-threatening diseases. It offers immunogl...
Industry Drug Manufacturers - General
Sector Healthcare
IPO Date Jun 2, 2011
Employees 23,833
Stock Exchange NASDAQ
Ticker Symbol GRFS
Website https://www.grifols.com
4 months ago
Grifols shares are trading lower after the company...
Unlock content with
Pro Subscription
4 months ago
+5.06%
Grifols shares are trading higher following a report suggesting banks are preparing to submit final offers for a buyout debt deal.
1 month ago · seekingalpha.com
Grifols: Looking At The Longer-Term 2025-2027 Upside After No SaleGrifols remains a strong long-term investment due to its leading position in the plasma industry and improving financial fundamentals, despite short-term volatility and lack of a dividend. The company...
